beLAB2122Funding programme for life science research

26 April 2022

To promote the translation of research results into clinical application, scientists from life science disciplines at Heidelberg University can apply for beLAB2122. Funding is open to all topics and an application for funding can be submitted at any time.

The beLAB2122 is a cooperative model - industry and academia, in which the universities of Frankfurt and Tübingen, as well as the DKFZ and the EMBL, are involved as additional scientific institutions alongside Heidelberg University. The industrial partners are Evotec and Bristol Myers Squibb, which also provide the funding.

In beLAB2122 BRIDGE (Biomedical Research, Innovation & Development Generation Efficiency), scientific projects with great innovation potential are supported on the way to application in an industrial cooperation with Evotec and Bristol Myers Squibb. The focus lies on validation on the way to market maturity. Projects are open to all topics, but should be at a stage where preclinical proof of concept can be achieved during the funding phase. Resulting intellectual property acts as an asset for the subsequent establishment of a start-up.

The project duration is up to 2 years. Depending on the scope of the project, funding of up to $1,500,000 USD is possible. A significant portion of the work should utilize Evotec's infrastructure (e.g. screening platforms).

Ideas can be presented on an ongoing basis. Project proposals and terms will initially be discussed internally. If suitable, the project will be presented to Evotec and after positive evaluation, joint project development with Evotec will take place. The funding decision is made after presentation of the project by Evotec and Bristol Myers Squibb.

Questions regarding content requirements and project proposals for beLAB2122 should be addressed to Dr. Christoph Meyer (christoph.meyer@zuv.uni-heidelberg.de).